Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR1797289

— · cohortMD2

b025ddca-31c3-5cf5-8ba8-a0d6ba7fa27b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2
age_years
59

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.470
  • ANGIOGENESIS+0.370
  • ALLOGRAFT_REJECTION+0.360
  • KRAS_SIGNALING_DN+0.350
  • TNFA_SIGNALING_VIA_NFKB+0.330
  • INFLAMMATORY_RESPONSE+0.320
  • COAGULATION+0.310
  • INTERFERON_GAMMA_RESPONSE+0.290
  • INTERFERON_ALPHA_RESPONSE+0.280
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270

Top 10 suppressed

  • E2F_TARGETS-0.550
  • MYC_TARGETS_V1-0.530
  • G2M_CHECKPOINT-0.510
  • OXIDATIVE_PHOSPHORYLATION-0.430
  • MITOTIC_SPINDLE-0.420
  • DNA_REPAIR-0.410
  • PROTEIN_SECRETION-0.370
  • UNFOLDED_PROTEIN_RESPONSE-0.300
  • MTORC1_SIGNALING-0.280
  • MYC_TARGETS_V2-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MDT-AP-2892
medullo-epn-umap@date-based
MedMedulloblastoma0.930
2SRR1397906
brain-umap@2
GTEX—0.929
3SRR1319539
brain-umap@2
GTEX—0.926
4SRR1472150
brain-umap@2
GTEX—0.924
5sclcA055A_S52.txt
lung-landscapes@6
—cohortMD20.924
6BS_YG0A13JH
brain-umap@2
pilocytic astrocytoma—0.923
7MDT-AP-1215
medullo-epn-umap@date-based
MedMedulloblastoma0.922
8SRR1797249
lung-landscapes@6
—cohortMD20.920
9SRR1317494
brain-umap@2
GTEX—0.917
10sclc55A_S50.txt
lung-landscapes@6
—cohortMD20.917

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.470Cobimetinib— uncovered
ANGIOGENESIS0.370Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.360Idelalisib— uncovered
KRAS_SIGNALING_DN0.350Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.330Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.320Idelalisib— uncovered
COAGULATION0.310Binimetinib— uncovered
INTERFERON_GAMMA_RESPONSE0.290Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.280Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.260Inavolisib— uncovered
HYPOXIA0.240Idelalisib— uncovered
IL2_STAT5_SIGNALING0.220Idelalisib— uncovered
COMPLEMENT0.210Inavolisib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
KRAS_SIGNALING_UP0.200Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
APOPTOSIS0.140Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.140Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered